The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Balancing the efficacy and toxicity of chemotherapy in colorectal cancer
Abstract
As the therapeutic options for the treatment of colorectal cancer have expanded over the past 20 years, so has the complexity of decision making. The goals of treatment in the palliative, adjuvant and neoadjuvant settings vary and it is not only the efficacy of drugs that influence treatment decisions. Age, performance status, the presence of significant comorbidities and the different treatment regimens and strategies provide medical oncologists with an array of options to attempt to maximize patients’ quality of life and longevity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the acquired drug resistance, short half-life of 10–20 min, and harmful side effects on the bone marrow and gastrointestinal tract (GIT), remain among the limitations of its clinical use [9,10].”
From Novel Green Biosynthesis of 5-Fluorouracil Chromium Nanoparticles Using Harpullia pendula Extract for Treatment of Colorectal Cancer (2021) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Hecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8135 · Cited by 850
Sargent, D. J., Köhne, C. H., Sanoff, H. K., Bot, B. M., Seymour, M. T., de Gramont, A., Porschen, R., Saltz, L. B., Rougier, P., Tournigand, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.2879 · Cited by 196
Self-citation
Flagged first, then by citations
Research works printed but not linked: 43
- 10.1038/sj.bjc.6604877 · DOI
- 10.1016/S1359-6349(09)72050-6 · DOI
- 10.1056/NEJMoa032709 · DOI
- 10.1200/JCO.2008.20.6771 · DOI
- Best L., 2000, Cochrane Database Syst Rev, CD001545
- 10.1200/JCO.2008.20.8397 · DOI
- 10.1093/annonc/mdf089 · DOI · Paper page
- 10.1200/JCO.2009.23.4344 · DOI
- 10.1200/JCO.1997.15.2.808 · DOI
- 10.1200/JCO.2000.18.16.2938 · DOI · Paper page
- 10.1016/S0140-6736(00)02034-1 · DOI · Paper page
- 10.1016/S1359-6349(09)72039-7 · DOI
- Falcone A., 2007, J Clin Oncol, 25, 1670, 10.1200/JCO.2006.09.0928 · DOI · Paper page
- 10.1093/annonc/mdi246 · DOI
- 10.1200/JCO.2004.09.046 · DOI
- 10.1200/JCO.2006.06.9039 · DOI
- 10.3816/CCC.2005.s.006 · DOI
- Jackson McLeary N.J., 2009, J Clin Oncol, 27
- 10.1056/NEJMoa0804385 · DOI · Paper page
- 10.1023/A:1008303229469 · DOI
- 10.1016/S0140-6736(07)61086-1 · DOI
- 10.1200/JCO.2006.08.6652 · DOI
- Ledermann J.A., 2001, N Engl J Med, 345, 145
- Maughan T., 2009, Eur J Cancer, 7, 4, abstract LBA, 10.1016/S1359-6349(09)72034-8 · DOI
- 10.1016/S0140-6736(03)12461-0 · DOI
- 10.1200/JCO.1998.16.1.301 · DOI
- 10.1200/JCO.1998.16.11.3537 · DOI
- 10.1016/S0140-6736(08)60455-9 · DOI
- 10.1093/annonc/mdn735 · DOI
- 10.1016/S0140-6736(07)61866-2 · DOI
- 10.1056/NEJM200009283431302 · DOI
- 10.1200/JCO.2007.11.2144 · DOI
- 10.1056/NEJM200107123450213 · DOI
- 10.1016/S0140-6736(07)61087-3 · DOI
- 10.1200/jco.2007.25.18_suppl.9030 · DOI
- 10.1002/cncr.24527 · DOI
- Souglakos J., 2006, Br J Cancer, 94, 798, 10.1038/sj.bjc.6603011 · DOI
- 10.1056/NEJMoa0808268 · DOI
- 10.1200/JCO.2005.03.0106 · DOI
- 10.1056/NEJMoa043116 · DOI
- 10.1200/JCO.2001.19.21.4097 · DOI
- Wolmark N., 2005, J Clin Oncol, 23, 10.1200/jco.2005.23.16_suppl.lba3500 · DOI
- Yothers, G.A., O'Connell, M.J., Colangelo, L., Kuebler, J.P., Lopa, S., Findlay, M.P. et al . (2010) 5-FU and leucovorin (Lv) with or without oxaliplatin (Ox) for adjuvant treatment of stage II and III colon cancer: Long-term follow-up of NSABP C-07 with survival analysis. In: Proceedings of the ASCO Gastrointestinal Cancers Symposium , Orlando, Florida, abstract 401.
Cited by
Sorted by citations
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
Tarantino, P., Ricciuti, B., Pradhan, S. M., & Tolaney, S. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00783-w · Cited by 269
Saddik, M. S., Elsayed, M. M. A., Abdelkader, M. S. A., El-Mokhtar, M. A., Abdel-Aleem, J. A., Abu-Dief, A. M., Al-Hakkani, M. F., Farghaly, H. S., & Abou-Taleb, H. A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020226 · Cited by 89
Bauleth-Ramos, T., Feijão, T., Gonçalves, A., Shahbazi, M.-A., Liu, Z., Barrias, C., Oliveira, M. J., Granja, P., Santos, H. A., & Sarmento, B. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.025 · Cited by 79
Metadata
- Authors
- Braun, M. S., & Seymour, M. T.
- Affiliations
- Consultant, Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK
- Section of Oncology and Clinical Research, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK
- Venue
- Therapeutic Advances in Medical Oncology
- Publisher
- SAGE Publications
- Published
- 2010-11-02
- Volume
- 3
- Issue
- 1
- Pages
- 43-52
- ISSN
- 1758-8359
- Cited by
- 100
- References
- 7
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
